Product development resource
How Supplement Tablets Are Formulated
Tablet formulation turns a dose into a blend that can flow, fill dies, compact, eject, survive handling and disintegrate as intended. Excipient choices must solve the actual material and process risks.
Short answer
A tablet formulation is not an active ingredient plus a standard excipient blend. It is a material system designed to deliver the target dose while flowing into the press, filling consistently, compacting into a robust unit, ejecting without damage and meeting performance and stability requirements.
The fastest route is often direct compression, but only when the ingredient system supports it. Otherwise, dry or wet granulation may be used to change powder behaviour before compression.
Evidence guide: Published evidence — supported by the linked technical source. · Development guidance — a practical way to frame or test the product, not a universal specification. · Manufacturer-specific — depends on the selected process, equipment and commercial arrangement. · Product-specific validation — must be demonstrated with the actual formula, process, pack and market.
Start with the active system
Characterize the actual commercial raw materials, not just their names.
Important inputs include:
- required amount and assay-adjusted input;
- particle size, morphology and density;
- flow and cohesiveness;
- compactability and elastic recovery;
- moisture or heat sensitivity;
- solubility and wetting where performance matters;
- taste, colour and odour;
- interactions with other ingredients;
- variability between suppliers or grades.
Two grades of the same ingredient can behave differently on a tablet press. Supplier substitution should therefore be governed by meaningful material specifications.
Choose excipients by function
| Excipient function | Why it may be used | What can go wrong |
|---|---|---|
| Filler/diluent | Builds tablet mass and can support compaction | Increases tablet size; may change stability or disintegration |
| Binder | Improves cohesion and strength | Excess or unsuitable binding can slow break-up |
| Disintegrant | Promotes break-up after exposure to fluid | Performance depends on type, level, location and process |
| Lubricant | Reduces die-wall friction and supports ejection | Excessive level or mixing can weaken bonding or wetting |
| Glidant | Improves powder movement in some blends | Does not cure every flow or segregation problem |
| Coating excipient | Supports film formation or functional coating | Adds process and stability variables |
This is a decision table, not a recipe. Excipient acceptability and labelling also depend on market and product classification.
Direct compression decision
Direct compression removes intermediate granulation and drying steps. It can reduce process complexity and avoid exposing ingredients to added moisture or heat.
It requires a blend with adequate:
- flow into the feed frame and dies;
- content uniformity;
- compactability at the intended press conditions;
- lubrication and ejection behaviour;
- robustness across press speed and hold time.
If those conditions are not met, adding more lubricant or compression force may simply move the failure elsewhere. The team may need a different ingredient grade, co-processed excipient, particle engineering or granulation route.
Wet and dry granulation
Wet granulation uses a liquid and binder system to form granules, followed by drying and size control. It can improve flow, density or distribution, but moisture, solvent, heat and additional processing must suit the ingredients.
Dry granulation compacts powder without a liquid, commonly through roller compaction, then mills it into granules. It can suit moisture-sensitive systems but introduces compaction history and can affect later tabletability.
The route should be selected from material risk and target product attributes. Granulation is not evidence that a formula is “higher quality,” and direct compression is not always simpler once performance failures are counted.
Tablet weight and content uniformity
Tablet weight is set by formulation mass and die fill. For a uniform blend, inconsistent die filling can still change unit mass. For a segregating blend, units can vary in composition even when total weight looks acceptable.
Development should distinguish:
- blend uniformity;
- tablet weight variation;
- assay;
- content uniformity where required.
Low-dose actives, large density differences and poor flow deserve particular attention. Sampling plans and acceptance criteria should match product and regulatory requirements.
Strength and performance trade-offs
Compression creates interparticle bonds and reduces pore space. Increasing compression may increase strength, but the resulting microstructure can alter liquid penetration, disintegration and dissolution.
Formulators therefore evaluate a response across a range of conditions rather than chasing one maximum hardness value. A useful development profile includes tablet weight, thickness, strength, friability, disintegration and any relevant release test, together with observations such as sticking, picking, capping or lamination.
Scale-up changes the operating context
At production scale, press speed, feeder design, dwell time, powder head, tooling condition and environmental exposure can differ from the laboratory. A formulation that works on a slow single-station press may not fill or compact identically on a rotary press.
Transfer the product with defined material attributes and a process range, not only a list of ingredients. Pilot work should identify which parameters affect the critical product attributes and which in-process controls detect drift.
A formulation brief manufacturers can use
Provide:
- complete formula and target tablet weight;
- ingredient grades and specifications;
- target dimensions, shape and serving count;
- proposed process route and supporting trials;
- desired coating and its purpose;
- relevant hardness/friability/disintegration or release targets;
- target markets and claims;
- packaging and shelf-life target;
- known sensitivities and unresolved risks.
Then use the tablet manufacturing process guide to align the formula with the production flow and the tablet format hub for the broader product decision.
Sources and evidence boundaries
- Portier, Vervaet and Vanhoorne, “Continuous Twin Screw Granulation: A Review of Recent Progress and Opportunities in Formulation and Equipment Design,” Pharmaceutics 13 (2021): 668. Full text
- Peddapatla et al., “Process Model Approach to Predict Tablet Weight Variability for Direct Compression Formulations at Pilot and Production Scale,” Pharmaceutics 13 (2021): 1033. Full text
- Markl and Zeitler, “A Review of Disintegration Mechanisms and Measurement Techniques,” Pharmaceutical Research 34 (2017): 890–917. Full text
- ICH, “Q8(R2) Pharmaceutical Development.” Official guideline
Published tablet science supports the relationships described here. Exact excipient levels, process settings and product specifications require formulation and manufacturing validation.